Thursday 16 October, 2025
Objectives: The challenge associated with lifelong combination antiretroviral treatments (cART) taken by HIV infected patients have motivated the development of…
Read moreAbstracts
Using population approach to model COVID-19 epidemics in France: estimating the burden of SARS-Cov-2 and the effects of non-pharmaceutical interventions.
Thursday 16 October, 2025
Objectives: The COVID-19 disease is an ongoing pandemics of coronavirus infection caused by SARS-CoV-2. Governments are taking a wide range…
Read morePopulation PK and PKPD modeling of TBA-7371 in Healthy Adults and Adults with tuberculosis
Thursday 16 October, 2025
Objectives: Develop a population pharmacokinetics (popPK) model that characterizes the PK of TBA-7371, a drug showing a potent bactericidal anti-Mycobacterium…
Read moreDolutegravir pharmacokinetics in co-administration with rifampicin.
Thursday 16 October, 2025
Objectives: Dolutegravir (DTG) is being introduced as first-line antiretroviral therapy across most of Africa. The antitubercular agent rifampicin (RIF) is…
Read moreDeveloping a shiny app to expedite the simulation of PKPD profiles of mAbS and exploration study designs
Thursday 16 October, 2025
Objectives: Monoclonal antibodies (mAbs) are an essential and expanding class of therapeutic agents [1]. MAbs possess a high degree of…
Read morePopulation pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)
Thursday 16 October, 2025
Objectives: Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of tenofovir, a nucleoside analogue that inhibits human immunodeficiency…
Read moreRifabutin changes dolutegravir’s half-life but not area under the curve when co-administered
Thursday 16 October, 2025
Objectives: Dolutegravir-based regimens are recommended as first-line HIV therapy in low and middle-income countries (LMIC). Rifampicin, the mainstay of tuberculosis (TB)…
Read moreA new computational approach to match control subjects to renal impaired patients in pharmacokinetic studies
Thursday 16 October, 2025
Introduction: Most of drugs that are likely to be administered to patients with renal impairment should be investigated in this…
Read moreSemi-mechanistic pharmacodynamics modeling of aztreonam-avibactam combination to understand its antimicrobial activity against multidrug-resistant Gram-negative bacteria
Thursday 16 October, 2025
Objectives: Aztreonam-avibactam (ATM-AVI) is a promising β-lactam-β-lactamase inhibitor combination to treat serious infections caused by multi-drug resistant (MDR) pathogens including…
Read moreA hybrid machine learning/pharmacokinetic approach improves predictive performance in model-informed precision dosing
Thursday 16 October, 2025
Objectives: Model-informed precision dosing (MIPD) typically leverages empirical Bayes estimates of pharmacokinetic (PK) parameters, allowing for individualization of treatment at…
Read more